Category Archives: Cancer and neoplasms

Identification and validation of a prognostic risk-scoring model based on the level of TIM-3 expression in acute myeloid leukemia

Abstract Acute myeloid leukemia (AML) is characterized by an unfavorable prognosis due to the presence of self-renewing leukemic stem cells (LSCs). The presence of T-cell immunoglobulin mucin-3 (TIM-3) on the surface of LSCs has been observed in various types of human AML, exerting an impact on the prognostic outcome. Exploring the hub genes associated with […]

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

Uwe Platzbecker, MD Data from ongoing phase 3 clinical trials could continue to alter the treatment landscape for patients with lower-risk myelodysplastic neoplasms (MDS), according to Uwe Platzbecker, MD. In an interview with OncLive®, Platzbecker, a professor of hematology and director of Medical Clinic I at the University Hospital of Leipzig in Germany, discussed these […]

ASX cancer stocks guide: Here’s everything you need to know

Link copied toclipboard According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. WHO says the one defining feature of cancer is the rapid […]

Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out – AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda

New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) — Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out – AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda The DLBCL market has a diverse pipeline, with the emergence of novel classes such as bi-specific […]

Metastatic Urothelial Carcinoma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Space | Companies – Eli Lilly and Company, QED Therapeutics, Bayer

“Metastatic Urothelial Carcinoma Market” DelveInsight’s “Metastatic Urothelial Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Metastatic Urothelial Carcinoma, historical and forecasted epidemiology as well as the Metastatic Urothelial Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. DelveInsight has launched a […]

Axi-Cel Yields High Responses in R/R High-Risk Large B-Cell Lymphoma

“ALYCANTE is the first study to assess [axi-cel] as second-line therapy for transplant ineligible R/R LBCL and the results showed high response rates and durable remission in this hard-to-treat population,” according to Roch Houot, professor and head of the Haematology Department at University Hospital of Rennes, France. Treatment with axicabtagene ciloleucel (Axi-cel; Yescarta) produced high […]

Ruxolitinib Receives Positive NICE Opinion for Polycythemia Vera

The FDA approved ruxolitinib as a treatment for patients with polycythemia vera who are intolerant to hydroxyurea in December 2014. The National Institute for Health and Care Excellence (NICE) has issued a final draft guidance recommending the approval of ruxolitinib (Jakafi) as a treatment for adult patients with polycythemia vera that is intolerant or resistant […]

16 gastroenterology updates

Here are 16 gastroenterology updates Becker’s has reported on since Aug. 25: 1. The Digestive Health Physicians Association issued a statement of support for the proposed Protecting Patient Access to Cancer Care and Complex Therapies act, introduced by three Republican senators and representatives.  2. U.S. Digestive Health partnered with Wilmington-based GI Specialists of Delaware. 3. […]